P717: BOSUTINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: GASTROINTESTINAL, LIVER, EFFUSION AND RENAL SAFETY CHARACTERIZATION IN THE BFORE TRIAL

• J. E. Cortes,
• D. Milojkovic,
• C. Gambacorti-Passerini,
• V. García-Gutiérrez,
• M. J. Mauro,
• E. Leip,
• S. Purcell,
• A. Viqueira,
• T. H. Brümmendorf

Affiliations

J. E. Cortes

1 Georgia Cancer Center, Augusta, United States of America

D. Milojkovic

2 Hammersmith Hospital, London, United Kingdom

C. Gambacorti-Passerini

3 University of Milano-Bicocca, Monza, Italy

V. García-Gutiérrez

4 Universitario Ramón y Cajal, Ramón y Cajal Health Research Institute, Madrid, Spain

M. J. Mauro

5 Memorial Sloan Kettering Cancer Center, New York

E. Leip

6 Pfizer Inc, Cambridge, United States of America

S. Purcell

7 Pfizer Ltd, London, United Kingdom

A. Viqueira

8 Pfizer SLU, Madrid, Spain

T. H. Brümmendorf

9 Universitätsklinikum RWTH Aachen, Aachen, Germany